Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trialRafael Rosell, Rolf A. Stahel, Oliver Gautschi et al.|The Lancet Respiratory Medicine|2017Cited by 184
Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung TrialSolange Peters, Egbert F. Smit, Rolf A. Stahel et al.|Journal of Thoracic Oncology|2016Cited by 22